CN117402839A - Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate - Google Patents
Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate Download PDFInfo
- Publication number
- CN117402839A CN117402839A CN202210830705.0A CN202210830705A CN117402839A CN 117402839 A CN117402839 A CN 117402839A CN 202210830705 A CN202210830705 A CN 202210830705A CN 117402839 A CN117402839 A CN 117402839A
- Authority
- CN
- China
- Prior art keywords
- ketoreductase
- mutant
- ethyl
- chloro
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- AKDAXGMVRMXFOO-GSVOUGTGSA-N (3r)-4-chloro-3-hydroxybutanoic acid Chemical compound ClC[C@H](O)CC(O)=O AKDAXGMVRMXFOO-GSVOUGTGSA-N 0.000 title description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 claims abstract description 21
- ZAJNMXDBJKCCAT-RXMQYKEDSA-N ethyl (3r)-4-chloro-3-hydroxybutanoate Chemical compound CCOC(=O)C[C@@H](O)CCl ZAJNMXDBJKCCAT-RXMQYKEDSA-N 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000006555 catalytic reaction Methods 0.000 claims description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 8
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 description 37
- 102000004190 Enzymes Human genes 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 241001055566 Lachnellula hyalina Species 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTNTYHJFWMUBD-UHFFFAOYSA-N 4-chloro-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)CCl UCTNTYHJFWMUBD-UHFFFAOYSA-N 0.000 description 1
- 241000379229 Abies koreana Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate ethyl ester. The ketoreductase disclosed by the invention has an amino acid sequence shown as SEQ ID NO. 1, and the mutant thereof has an amino acid sequence shown as SEQ ID NO. 3. The ketoreductase and the mutant thereof provided by the invention can realize the reaction of efficiently catalyzing the conversion of the 4-chloroacetoacetic acid ethyl ester into the (R) -4-chloro-3-hydroxybutyric acid ethyl ester.
Description
Technical Field
The invention belongs to the technical field of functional enzyme screening, and relates to ketoreductase from Lachnellula hyalina, mutants thereof, nucleic acid molecules encoding the ketoreductase, vectors and cells containing the nucleic acid molecules, a preparation method of the ketoreductase, the mutants, and application of the nucleic acid molecules in preparation of (R) -4-chloro-3-hydroxybutyrate.
Background
L-carnitine is initially found in red meat extracts, is mainly responsible for transporting long-chain fatty acid into mitochondria to oxidize in human bodies, is widely applied to the fields of medicines, health-care products and the like, and is prepared by a chemical synthesis method at present. The (R) -4-chloro-3-hydroxybutyric acid ethyl ester ((R) -CHBE) is an important chiral intermediate and can be widely used for preparing chiral medicines such as L-carnitine and afatinib. The L-carnitine and derivative salts thereof can be prepared by ammonification, hydrolysis and deionized. The method takes 4-chloroacetoacetic acid ethyl ester as a substrate, is catalyzed by a chiral catalyst (a metal catalyst prepared by rare metals) which is the main means for preparing (R) -4-chloro-3-hydroxybutyric acid ethyl ester at present, the chiral catalyst is being replaced by an attempt to seek a green biocatalysis and fermentation method, and is the most suitable method for preparing L-carnitine by the catalysis of biological enzymes at present.
The biological enzyme is used for catalyzing the 4-chloroacetoacetic acid ethyl ester to prepare the (R) -4-chloro-3-hydroxybutyric acid ethyl ester, the ketoreductase is used for catalyzing the preparation, and a certain amount of reduced Nicotinamide Adenine Dinucleotide (NADH) is required to be added as coenzyme to participate in the reaction process. At present, the preparation of the (R) -4-chloro-3-hydroxy ethyl butyrate based on a biological enzyme or biological fermentation mode does not enter an industrial production stage, so that further excavation, discovery and modification of the biological enzyme capable of catalyzing the reaction are needed, and the requirement of industrially producing the (R) -4-chloro-3-hydroxy ethyl butyrate can be met.
Disclosure of Invention
The invention aims to provide ketoreductase, a mutant thereof, a coding gene and application thereof, so as to improve the enzyme activity, the repeated use stability and the conversion rate of catalytic synthesis (R) -CHBE.
According to the invention, ketoreductase KREDLH is obtained from Lachnellula hyalina bacterial strain, the amino acid sequence of the ketoreductase KREDLH is shown as SEQ ID NO. 1, the nucleotide sequence of the ketoreductase KREDLH is shown as SEQ ID NO. 2, and the ketoreductase mutant KREDLH-M which is obviously improved in enzyme activity, conversion rate and repeated use stability is obtained by further carrying out mutation treatment on the ketoreductase KREDLH, the amino acid sequence of the ketoreductase KREDLH-M is shown as SEQ ID NO. 3, and the nucleotide sequence of the ketoreductase mutant KREDLH-M is shown as SEQ ID NO. 4.
In a first aspect, the present invention provides a ketoreductase having the amino acid sequence set forth in SEQ ID NO. 1.
The ketoreductase provided by the invention can be synthesized artificially, or the encoding gene of the ketoreductase can be synthesized first and then biologically expressed, for example, the ketoreductase is obtained by expressing the ketoreductase from escherichia coli by using a recombination technology.
In some embodiments, the ketoreductase is a recombinant genetically engineered strain constructed by transforming a recombinant vector containing a gene encoding the same into an E.coli expression host (e.g., E.coli BL21 (DE 3)), then culturing the strain, and adding an inducer to induce expression to obtain the ketoreductase.
In a second aspect, the present invention provides a nucleic acid molecule encoding the ketoreductase described above, having the nucleotide sequence set forth in SEQ ID NO. 2.
The above nucleic acid molecules provided by the present invention can be obtained usually by amplification using a PCR instrument or artificial synthesis.
In a third aspect, the present invention provides a mutant of the above ketoreductase having an amino acid sequence shown in SEQ ID NO. 3, which has further improved catalytic activity, reuse stability and conversion rate as compared to the above ketoreductase. The mutant of the ketoreductase provided by the invention can be synthesized artificially, or can be obtained by synthesizing the coding gene and then biologically expressing the coding gene, for example, the coding gene is obtained by expressing the coding gene from a prokaryote (escherichia coli) by using a recombination technology.
In some embodiments, the ketoreductase mutant is obtained by transforming a recombinant vector containing the encoding gene into an escherichia coli expression host (e.g. e.coli BL21 (DE 3)) to construct a recombinant genetically engineered bacterium, culturing the strain, and adding an inducer to induce expression.
In a fourth aspect, the present invention provides a nucleic acid molecule encoding a ketoreductase mutant as described above, having the nucleotide sequence set forth in SEQ ID NO. 4.
The above nucleic acid molecules provided by the present invention can be obtained usually by amplification using a PCR instrument or artificial synthesis.
In a fifth aspect, the invention provides a recombinant vector comprising a nucleic acid molecule as described in any one of the preceding claims.
In some embodiments, the recombinant vector is pET-KREDLH or pET-delta KREDLH-M61, and the remaining sequence is obtained by replacing the EcoRI and HindIII cleavage site sequences of pET-28a (+) with the nucleic acid molecule encoding the ketoreductase or the ketoreductase mutant, respectively.
In a sixth aspect, the invention provides a recombinant cell comprising a recombinant vector as described in any one of the preceding claims.
In some embodiments, the recombinant cell expresses the ketoreductase or a mutant of the ketoreductase described above after induction.
In some embodiments, the method of constructing a recombinant cell comprises the following:
the recombinant vector is transformed into an expression host cell, and the expression is induced by culturing and adding an inducer, so that the ketoreductase or the mutant of the ketoreductase is obtained.
Further, the recombinant vector is any one of the above recombinant vectors, and the expression host cell is a prokaryotic cell or a eukaryotic cell, for example, escherichia coli, yeast, and the like, preferably escherichia coli expression host e.coli BL21 (DE 3).
In some embodiments, the recombinant cells are recombinant bacteria KE and recombinant bacteria 61, and the recombinant cells may be recombinant genetically engineered bacteria. The culture medium used when the recombinant genetically engineered bacterium expresses the ketoreductase or a mutant thereof may be a culture medium, such as a TB culture medium, which is known in the art to allow the recombinant genetically engineered bacterium to grow and express the ketoreductase or a mutant thereof of the present invention.
The culture method and the culture conditions have no special requirements, the normal growth of the recombinant genetic engineering strain is ensured, and the ketoreductase and the mutant thereof are induced and expressed at 18 ℃.
More specifically, the construction method of the recombinant cell comprises the following steps:
(1) Amplifying a ketoreductase gene KREDLH;
(2) Obtaining a gene delta KREDLH-M61 of the ketoreductase mutant;
(3) Constructing recombinant expression plasmids pET-KREDLH and pET-delta KREDLH-M61;
(4) Recombinant expression plasmids pET-KREDLH and pET-delta KREDLH-M61 are transformed into host cells;
(5) Screening a plate resistance culture medium to obtain a positive clone strain;
in a seventh aspect, the present invention provides a method for preparing a ketoreductase or a mutant thereof, comprising:
culturing any recombinant cell and adding an inducer for induction to obtain a culture;
isolating the ketoreductase or ketoreductase mutant described above from the culture;
among them, the method of culturing and inducing recombinant cells, and the method of separating ketoreductase and its mutants from the culture are all conventional methods in the art.
In an eighth aspect, the present invention provides the use of a ketoreductase as described above, a nucleic acid molecule as described above, a mutant of a ketoreductase as described above, a recombinant vector as described above, a recombinant cell as described above and a ketoreductase as prepared by the method as described above, and a mutant thereof, for the preparation of ethyl (R) -4-chloro-3-hydroxybutyrate, which can be further used for the preparation of L-carnitine and its derivative salts.
In a ninth aspect, the present invention provides a process for preparing (R) -4-chloro-3-hydroxybutyric acid ethyl ester, comprising: and (3) carrying out catalytic reaction on the ethyl 4-chloroacetoacetate by taking the ketoreductase, the ketoreductase mutant, the recombinant cell or the ketoreductase or the mutant thereof prepared by the method as a catalyst to obtain the (R) -4-chloro-3-hydroxybutyrate.
In some embodiments, in the above catalytic reactions, the temperature is 25-35 ℃, e.g., 25 ℃, 30 ℃, 35 ℃, or a value or range between any two of these values, with 30 ℃ being preferred as the reaction temperature; the initial pH is 6.0-7.0, and the pH of the reaction can be adjusted, for example to pH 6.8, using Tris or HCl (e.g., 500mM Tris and 1M hydrochloric acid).
The catalytic reaction comprises ethyl 4-chloroacetoacetate, isopropanol, and NADH;
the concentration of ethyl 4-chloroacetoacetate is 100-200g/L, for example 100g/L, 120g/L, 140g/L, 160g/L, 180g/L, 200g/L, or a value or range between any two of these values, preferably 140g/L;
the isopropanol is added in an amount of 2-3% (volume percent), preferably 3%;
the concentration of NADH is 1-10mM, e.g., 1mM, 2mM, 4mM, 6mM, 8mM, 10mM, or a value or range between any two of these values, with 5mM being preferred.
In some embodiments, the recombinant cell comprising any of the above-described catalytic reactions catalyzes the reaction of ethyl 4-chloroacetoacetate to produce ethyl (R) -4-chloro-3-hydroxybutyrate;
specifically, the recombinant cells or the freeze-dried powder thereof can be used as a catalyst for whole-cell catalytic production of (R) -4-chloro-3-hydroxybutyric acid ethyl ester, and if the catalyst is the freeze-dried powder, the dosage of the catalyst is 0.1-0.25g/g of 4-chloroacetoacetic acid ethyl ester, preferably 0.2g/g of 4-chloroacetoacetic acid ethyl ester; if the catalyst is a culture solution of recombinant cells, the dosage of the catalyst can be 400-600 mu L of bacterial liquid/ml of reaction system, wherein the OD of the bacterial liquid 600 1.8-2.2, e.g. 500. Mu.L OD 600 2 bacteria liquid/ml reaction system.
It will be appreciated that the ketoreductase KREDLH or mutant KREDLH-M of the present invention may be used in the form of whole cells of an engineering bacterium, as a crude enzyme without purification, or as a partially purified or completely purified enzyme. The ketoreductase KREDLH or mutants thereof of the present invention may also be prepared into immobilized enzymes or immobilized cell forms of catalysts using immobilization techniques known in the art.
The ketoreductase and the mutant thereof can efficiently catalyze and synthesize (R) -4-chloro-3-hydroxy ethyl butyrate, particularly the mutant thereof, under proper conditions, 4-chloroacetoacetic acid ethyl ester is taken as a substrate, the conversion rate is 82.6%, the enzyme activity is 236.8U/L, which is 1.415 times of the original enzyme, and the stability is better than that of the original enzyme.
Drawings
FIG. 1 is a gas chromatogram of a standard of ethyl 4-chloroacetoacetate.
FIG. 2 is a gas chromatogram of (R) -4-chloro-3-hydroxybutyric acid ethyl ester standard.
FIG. 3 is a gas chromatogram of the reaction solution.
Detailed Description
The invention will be further illustrated with reference to specific examples. It should be understood that the following examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Unless otherwise indicated, all technical means used in the examples are routine in the art or according to the experimental methods suggested by the manufacturers of the kits and instruments. Reagents and biological materials used in the examples were obtained commercially unless otherwise specified.
Strain Lachnellula hyalina is disclosed in the literature "H Park, kim, d.y., kim, s.r., & Eom, a.h. (2018) New records of endophytic fungi isolated from leaves of abies koreana and taxus cuspidata in korea. The Korean Journal of Mycology,46 (3), 241-248," publicly available from the vandergar chemical group inc.
pET-28a (+) is a product of the division of biological engineering (Shanghai) and has a catalog number of B540183.
Example 1: obtaining of the Gene sequence of ketoreductase KREDLH
1. Genomic DNA of Lachnellula hyalina was extracted.
2. And (3) taking the genomic DNA of Lachnellula hyalina as a template, and taking a primer 1 (5'-ggaattccatgaaggtctttctgagcggagg-3', SEQ ID NO: 5) and a primer 2 (5'-cccaagcttgggtcactccttatataatccctctttcgggtaatc-3', SEQ ID NO: 6) as primer pairs to perform PCR, so as to obtain a PCR amplified fragment containing a ketoreductase gene, wherein the nucleotide sequence of the ketoreductase gene is shown as SEQ ID NO:2, and the amino acid sequence of the coded ketoreductase is shown as SEQ ID NO: 1.
MKVFLSGGSGFIAAHVLDILLEHGHTVITSVRSQEKANKIKEAHPNTPASQLEFRIVKDIAQEGAFDEAIKIDGLEAVIHTASPFHFNVTDVKKDLLDPAIIGTTGILKAIKKNAPSVKRVVITSSFASIVNPSKGNSWTEHTYSEEDWNPITEEEAVLNPSNGYRASKTFAEKAAWEFVEKEKPNFTLSTMCPPLVIGPIVHYLNSLDSLNTSNQRTANLMTGKNKSEIPDTGTYIWIDVRDLALAHVKAIELPEAANKRFFITAGYFSNKEIAEIIRKNFPALEKELPAKDVKGGDYPKEGLYKE(SEQ ID NO:1)
atgaaggtctttctgagcggaggaagtggcttcatcgccgcccacgtcctcgacatcctactcgagcatggccatactgtcatcacctcggttcgttcccaagagaaagccaacaagatcaaagaggcgcaccccaacacgcctgcctcccagctcgagttccggattgtcaaagacatagcacaggagggggcctttgacgaagccatcaagattgacggcctggaagcggtgattcacacagcctcgcctttccatttcaacgtcacagatgtcaagaaagacttgcttgaccctgccataatcggcacaacaggtatcctgaaagccatcaagaagaatgctcccagcgtgaagagagtcgtcatcacgagttcctttgccagcatcgtcaatccaagtaagggaaactcctggaccgagcacacgtacagcgaggaggactggaaccccatcacggaagaagaggcggtgctgaaccccagcaatggatacagagccagcaagacgttcgccgagaaagctgcgtgggagtttgtcgagaaggagaaaccaaactttacgttgagcactatgtgccctcctttagttataggtccaattgtccactacctcaacagcctcgatagcctcaacacctctaaccagcgaaccgccaacctcatgaccggcaagaacaagtctgaaatccccgacaccggtacctacatctggatcgatgtgcgagatctcgccctcgcccacgtcaaagccatcgagctcccagaagccgcgaacaagcgattcttcatcaccgctggttacttctccaacaaggagatcgctgagattatccgcaagaacttccccgcgctcgaaaaggaattgccggcgaaggacgtcaagggtggagattacccgaaagagggattatataaggagtga(SEQ ID NO:2)
Example 2: obtaining the gene sequence of ketoreductase mutant KREDLH-M by error-prone PCR technique
The following error-prone PCR was performed using the PCR amplified fragment obtained in example 1 as a template and primer 1 and primer 2 as a primer pair, to obtain 84 mutants of the ketoreductase gene in total.
Error-prone PCR reaction system: 5 μl of 10 Xamplification buffer, 4 μl of each of 4 dNTP mixtures (2.5 mmol/L), 50pmol of each primer, 1.5 μg of template DNA, 0.5 μl of Taq DNA polymerase, mg 2+ 7mmol/L, double distilled water was added to 50. Mu.l.
PCR reaction procedure: (1) Pre-denaturation: 94 ℃ for 3min; (2) denaturation: 94 ℃ for 30s; annealing: 58 ℃ for 30s; extension: 72 ℃ for 1.5min; cycling 40 times altogether; (3) post-extension: 72 ℃ for 10min; (4) incubation at 4 ℃.
Example 3: cloning of ketoreductase Gene and construction of expression Strain
1. The PCR amplified fragment containing the ketoreductase gene obtained in example 1 was digested simultaneously with EcoRI and HindIII to obtain a gene fragment; double-enzyme cutting pET-28a (+) by EcoRI and HindIII to obtain a vector fragment; the gene fragment and the vector fragment were ligated to obtain a recombinant expression plasmid, which was designated as pET-KREDLH, and the plasmid was subjected to sequencing, and the result was consistent with that expected.
2. And (3) transferring the recombinant expression plasmid pET-KREDLH obtained in the step (1) into E.coli DH5 alpha competent cells through heat shock, coating LB solid medium containing 25 mu g/mL kanamycin, culturing to obtain corresponding monoclonal strains, naming the corresponding monoclonal strains as K, amplifying and extracting the plasmids to obtain pET-KREDLH plasmids, transferring the obtained plasmids into an expression host E.coli BL21 (DE 3) through a chemical conversion mode, coating LB solid medium containing 25 mu g/mL kanamycin, and screening to obtain recombinant bacteria KE expressing ketoreductase.
Example 4: cloning of ketoreductase mutant Gene and construction of expression Strain
Recombinant plasmids pET-. DELTA.KREDLH-M1 to pET-. DELTA.KREDLH-M84 were each constructed by the same method as in example 3 using 84 mutants of the ketoreductase gene obtained in example 2, and recombinant 1-recombinant 84 expressing the ketoreductase mutants was obtained.
Example 5: high throughput screening of ketoreductase mutants
The recombinant bacteria of examples 3 and 4, which were confirmed to be correct by PCR, were cultured in 5mL of TB medium, respectively, and protein expression was induced at 18℃by adding IPTG at a final concentration of 0.6mM, and after 12 hours, the OD of the bacterial solution was measured 600 Value, and diluting the bacterial liquid with water to make OD 600 The value is about 2. 1.2ml of a catalytic reaction system is designed in a deep hole 96-well plate, the initial pH is adjusted to 6.8, and the reaction system comprises 600 mu L of diluted bacterial liquid, 168mg of ethyl 4-chloroacetoacetate, 3.0% of isopropanol by volume percent and 5mM of NADH, and the volume is complemented by PBS. The well plate for the incubation reaction was incubated at 30℃for 5 hours in a 120rpm mixer, and after the reaction was completed, 200. Mu.L of HCl at a concentration of 2M was added to terminate the reaction.
After the reaction, 50. Mu.L of the supernatant was added with 200. Mu.L of pure water, and the mixture was stirred and subjected to scanning at 340nm to measure absorbance.
The plasmid of the strain (recombinant bacterium 61) corresponding to the reaction solution with the lowest absorbance value is extracted, and sequencing is carried out to obtain the gene sequence of the coded ketoreductase mutant shown as SEQ ID NO. 4, and the amino acid sequence of the coded ketoreductase mutant is shown as SEQ ID NO. 3. Compared with the amino acid sequence SEQ ID NO. 1 of the wild ketoreductase, the ketoreductase mutant has the following mutation: the 41 st amino acid K is mutated to T, the 129 th amino acid S is mutated to N, the 180 th amino acid V is mutated to A, and the 272 th amino acid K is mutated to Q.
MKVFLSGGSGFIAAHVLDILLEHGHTVITSVRSQEKANKITEAHPNTPASQLEFRIVKDIAQEGAFDEAIKIDGLEAVIHTASPFHFNVTDVKKDLLDPAIIGTTGILKAIKKNAPSVKRVVITSSFANIVNPSKGNSWTEHTYSEEDWNPITEEEAVLNPSNGYRASKTFAEKAAWEFAEKEKPNFTLSTMCPPLVIGPIVHYLNSLDSLNTSNQRTANLMTGKNKSEIPDTGTYIWIDVRDLALAHVKAIELPEAANKRFFITAGYFSNQEIAEIIRKNFPALEKELPAKDVKGGDYPKEGLYKE(SEQ ID NO:3)
atgaaggtctttctgagcggaggaagtggcttcatcgccgcccacgtcctcgacatcctactcgagcatggccatactgtcatcacctcggttcgttcccaagagaaagccaacaagatcacagaggcgcaccccaacacgcctgcctcccagctcgagttccggattgtcaaagacatagcacaggagggggcctttgacgaagccatcaagattgacggcctggaagcggtgattcacacagcctcgcctttccatttcaacgtcacagatgtcaagaaagacttgcttgaccctgccataatcggcacaacaggtatcctgaaagccatcaagaagaatgctcccagcgtgaagagagtcgtcatcacgagttcctttgccaacatcgtcaatccaagtaagggaaactcctggaccgagcacacgtacagcgaggaggactggaaccccatcacggaagaagaggcggtgctgaaccccagcaatggatacagagccagcaagacgttcgccgagaaagctgcgtgggagtttgccgagaaggagaaaccaaactttacgttgagcactatgtgccctcctttagttataggtccaattgtccactacctcaacagcctcgatagcctcaacacctctaaccagcgaaccgccaacctcatgaccggcaagaacaagtctgaaatccccgacaccggtacctacatctggatcgatgtgcgagatctcgccctcgcccacgtcaaagccatcgagctcccagaagccgcgaacaagcgattcttcatcaccgctggttacttctccaaccaggagatcgctgagattatccgcaagaacttccccgcgctcgaaaaggaattgccggcgaaggacgtcaagggtggagattacccgaaagagggattatataaggagtga(SEQ ID NO:4)
Ethyl 4-chloroacetoacetate and NADH under the catalysis of ketoreductase(R) -4-chloro-3-hydroxybutyric acid ethyl ester and NAD were produced + The reaction formula of (2) is as follows:
example 6: preparation of enzyme and measurement of enzyme Activity
Recombinant bacteria KE obtained in example 3 and recombinant bacteria 61 obtained by screening in example 5 were subjected to expansion culture, and after expansion culture, the fermentation broth was subjected to centrifugation (8000 rpm,10 min), cell disruption, and freeze-drying to obtain lyophilized powders of ketoreductase (original enzyme) and mutants thereof (mutant enzyme), and stored at-80 ℃.
The enzyme activity unit (U) is defined as: under the reaction conditions of example 5 (final concentration of lyophilized powder of 0.2g/g ethyl 4-chloroacetoacetate), the amount of enzyme required to catalyze the production of 1. Mu. Mol of ethyl (R) -4-chloro-3-hydroxybutyrate per minute or the amount of enzyme required to consume 1. Mu. Mol of substrate ethyl 4-chloroacetoacetate per minute.
The enzyme activities of the original enzyme and the mutant enzyme are 167.35U/L and 236.8U/L respectively, compared with the original enzyme, the enzyme activity of the mutant enzyme is 1.415 times that of the original enzyme, and the conversion rates of the original enzyme and the mutant enzyme are 76.8% and 82.6% respectively by analyzing the residual amount of the substrate 4-chloroacetoacetate through gas chromatography.
The gas chromatography detection method comprises the following steps:
after the reaction, taking the reaction solution, centrifuging, taking 400 mu L of supernatant, adding 800 mu L of ethyl acetate, uniformly mixing, performing film passing, and then using gas chromatography to analyze the conversion rate, wherein an Agilent DB-5 capillary column is used, carrier gas is nitrogen, a hydrogen ion detector is used, the temperature of a sample inlet is 250 ℃, the temperature of the detector is 250 ℃, the temperature of a column temperature box is 90 ℃, the sample injection amount is 1 mu L, and the column flow rate is 1mL/min.
The gas chromatograms of the ethyl 4-chloroacetoacetate standard and the ethyl (R) -4-chloro-3-hydroxybutyrate standard are respectively shown in figures 1 and 2, the peak time of the ethyl 4-chloroacetoacetate is 6.598min, and the peak time of the ethyl (R) -4-chloro-3-hydroxybutyrate is 7.022min.
The gas chromatogram of the reaction solution was shown in FIG. 3, in which the peak time of ethyl (R) -4-chloro-3-hydroxybutyrate was 7.018min and the peak time of ethyl 4-chloroacetoacetate was 6.612min.
Example 7: enzyme stability test
A small amount of the lyophilized powder of the original enzyme and the mutant enzyme obtained in example 6 was reacted under the reaction conditions of example 5, and after the reaction was completed, the reaction was repeated by centrifugation to recover the enzyme, and the conversion rates of the two enzymes in each reaction batch were shown in Table 1.
TABLE 1
The result shows that the mutant enzyme has better recycling property, the conversion rate can still reach more than 80% after the reaction is carried out for 6 batches, the mutant enzyme has better stability compared with the original enzyme, the activity of the original enzyme is reduced by 12.37% after the reaction is carried out for 6 batches, and the activity of the recombinase is reduced by only 2.67%.
Claims (10)
1. A ketoreductase having the amino acid sequence shown in SEQ ID NO. 1.
2. A nucleic acid molecule encoding the ketoreductase of claim 1 having the nucleotide sequence set forth in SEQ ID No. 2.
3. A mutant of ketoreductase as claimed in claim 1, having the amino acid sequence shown in SEQ ID NO. 3.
4. A nucleic acid molecule encoding a mutant of a ketoreductase as claimed in claim 3, having the nucleotide sequence set forth in SEQ ID NO. 4.
5. A recombinant vector comprising the nucleic acid molecule of claim 2 or 4.
6. A recombinant cell comprising the recombinant vector of claim 5.
7. A method for preparing a ketoreductase or mutant thereof, comprising the steps of:
1) Culturing the recombinant cell of claim 6 and inducing expression of a ketoreductase or mutant thereof;
2) Isolating the ketoreductase of claim 1 or the variant of the ketoreductase process of claim 3 from the culture obtained in 1).
8. Use of a ketoreductase according to claim 1, a nucleic acid molecule according to claim 2, a mutant of a ketoreductase according to claim 3, a nucleic acid molecule according to claim 4, a recombinant vector according to claim 5, a recombinant cell according to claim 6 and/or a ketoreductase prepared by a method according to claim 7 or a mutant thereof for the preparation of ethyl (R) -4-chloro-3-hydroxybutyrate.
9. A preparation method of (R) -4-chloro-3-hydroxybutyric acid ethyl ester comprises the following steps: the ketoreductase of claim 1, the mutant of ketoreductase of claim 3, the recombinant cell of claim 6 and/or the ketoreductase or the mutant thereof prepared by the method of claim 7 are used as catalysts for catalyzing the conversion of ethyl 4-chloroacetoacetate into ethyl (R) -4-chloro-3-hydroxybutyrate.
10. The method of manufacturing according to claim 9, wherein: the catalytic reaction conditions are as follows: the temperature is 25-35 ℃, the pH is 6.0-7.0, and the reaction batch comprises: ethyl 4-chloroacetoacetate, isopropanol, and NADH;
the final concentration of the ethyl 4-chloroacetoacetate is 100-200g/L;
the volume percentage of the isopropanol is 2-3%;
the final concentration of NADH is 1-10mM.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210830705.0A CN117402839A (en) | 2022-07-15 | 2022-07-15 | Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210830705.0A CN117402839A (en) | 2022-07-15 | 2022-07-15 | Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117402839A true CN117402839A (en) | 2024-01-16 |
Family
ID=89491343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210830705.0A Pending CN117402839A (en) | 2022-07-15 | 2022-07-15 | Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117402839A (en) |
-
2022
- 2022-07-15 CN CN202210830705.0A patent/CN117402839A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109468291B (en) | Carbonyl reductase EbSDR8 mutant and construction method and application thereof | |
CN112877307B (en) | Amino acid dehydrogenase mutant and application thereof | |
CN109055324B (en) | Improved ketoreductase and application thereof | |
CN111411128B (en) | Whole cell biocatalysis method for producing alpha, omega-dicarboxylic acid and application thereof | |
CN111454918B (en) | Enol reductase mutant and application thereof in preparation of (R) -citronellal | |
CN109055417B (en) | Recombinant microorganism, preparation method thereof and application thereof in production of coenzyme Q10 | |
CN116814572A (en) | Carbonyl reductase and mutant thereof and application of carbonyl reductase and mutant in preparation of chiral (R) -8-chloro-6-hydroxy ethyl octanoate | |
CN115747183A (en) | Ketoreductase mutant and application thereof | |
CN116083387A (en) | Enzyme, strain for producing salidroside and production method | |
CN114908129B (en) | Dehydrogenase for the preparation of (R) -4-chloro-3-hydroxybutyric acid ethyl ester | |
CN113652408B (en) | Carbonyl reductase mutant and application thereof in synthesis of (R) -4-chloro-3-hydroxybutyrate ethyl ester | |
US11760988B2 (en) | L-aspartate alpha-decarboxylase mutant and application thereof | |
CN117402839A (en) | Ketoreductase and application thereof in preparation of (R) -4-chloro-3-hydroxybutyrate | |
EP2316926B1 (en) | Enantioselective production of alpha-hydroxy carbonyl compounds | |
CN111575258B (en) | Carbonyl reductase EbSDR8 mutant and construction method and application thereof | |
CN114752572B (en) | Formate dehydrogenase mutant and application thereof | |
CN117402843A (en) | Ketoreductase from schizosaccharomyces japonica yFS275 and application thereof | |
CN115029329B (en) | Carbonyl reductase mutant and application thereof in preparation of R-mandelic acid | |
CN114891820B (en) | Bacillus licheniformis for efficiently synthesizing hydroxytyrosol, construction method and application | |
CN114480315B (en) | Baeyer-Villiger monooxygenase and application thereof in brivaracetam synthesis | |
CN116790569B (en) | Pyruvic acid decarboxylase mutant and application thereof in preparation of alpha-hydroxyketone compound | |
CN114196659B (en) | Amidase mutant, coding gene, engineering bacteria and application thereof | |
CN117721088A (en) | Glucose dehydrogenase mutant and use thereof | |
CN117402847A (en) | 4-aminobutyric acid transaminase and encoding gene and application thereof | |
CN117904215A (en) | Method for producing tyrosol, engineering strain and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |